 Stealth BioTherapeutics Corp NASDAQ:MITO has earned a consensus rating of Hold from the seven research firms that are currently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokerages that have ... 